Post A Reply
my profile
login
|
register
|
search
|
faq
|
forum home
»
Allstocks.com's Bulletin Board
»
Micro Penny Stocks, Penny Stocks $0.10 & Under
»
DNAG>>> Gapping on news
» Post A Reply
Post A Reply
Login Name:
Password:
Message Icon:
Message:
HTML is not enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by Persia: [QB] DNAPrint genomics Receives Notice of Allowance for Patent for Processing Gene Sequence Data 10/27/05 SARASOTA, Fla., Oct 27, 2005 (PRIMEZONE via COMTEX) -- DNAPrint genomics, Inc. (OTCBB:DNAG), a developer of genomics-based products and services, today announced that it has been granted a notice of allowance from the U.S. Patent and Trademark Office for its patent application for Efficient Methods and Apparatus for High-Throughput Processing of Gene Sequence Data. "Though we are all 99.9% identical at the level of our DNA, it is the 0.1% difference called polymorphism that accounts for our individuality," stated Tony N. Frudakis, Ph.D., DNAPrint's founder and Chief Scientific Officer. "The technology our patent application covers relates to methods useful for measuring polymorphisms in and around genes that are part of large gene families, a task that traditionally has been problematic for the molecular genetics community." Geneticists use "molecular addresses" to query and study specific genes much like a postman uses a street address to find the recipient of a letter. The methods covered in the patent are useful when there are several genes with the same or substantially similar "sequence" addresses. Many of the genes that are involved in drug metabolism and response are members of large gene families. This is the first patent for which the Company applied. The methods covered in the application, first drafted in 2001, were originally developed to power DNAPrint's unique approach to pharmacogenomics research, which is aimed at understanding why people respond uniquely to drugs. About DNAPrint genomics, Inc. DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWITNESS, RETINOME, ANCESTRYbyDNA and EURO-DNA. [/QB][/QUOTE]
Instant Graemlins
Instant UBB Code™
What is UBB Code™?
Options
Disable Graemlins in this post.
*** Click here to review this topic. ***
Contact Us
|
Allstocks.com Message Board Home
© 1997 - 2021 Allstocks.com. All rights reserved.
Powered by
Infopop Corporation
UBB.classic™ 6.7.2